AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
Rhea-AI Summary
AEON (NYSE American: AEON) reported final, expanded primary structure results and preliminary disulfide bond data for ABP-450, its proposed biosimilar to BOTOX for therapeutic use. Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed.
According to AEON, preliminary disulfide characterization showed the same single interchain disulfide bond C430-C454 linking light and heavy chains in both ABP-450 and BOTOX across all tested lots, representing about 99% of total species. The FDA previously indicated AEON’s analytical similarity strategy under the 351(k) biosimilar pathway appeared reasonable, and the company expects additional BPD Type 2b feedback in the second half of 2026 to guide the next development phase.
Positive
- Active neurotoxin sequence coverage increased to 98% from approximately 93%
- Observed 100% amino acid identity across all analyzed regions in both products
- Single C430-C454 disulfide bond represents about 99% of species in each product
- FDA BPD Type 2a meeting supported planned analytical development approach
- Analyses performed across six drug product samples and multiple lots
Negative
- Primary structure coverage remains at 98%, not yet 100% of the active neurotoxin
- Disulfide bond characterization is described as preliminary, indicating further analytical work ahead
- Next development steps, including clinical pharmacology and comparative studies, await future FDA feedback
News Explained
The reported
Market Reaction – AEON
Following this news, AEON has declined 4.41%, reflecting a moderate negative market reaction. Argus tracked a peak move of +34.0% during the session. Argus tracked a trough of -17.1% from its starting point during tracking. Our momentum scanner has triggered 36 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.23. Trading volume is exceptionally heavy at 1696.6x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | 2Q26 earnings report | Neutral | -1.6% | Quarterly results, FDA progress, financing, and continued operating losses |
| Aug 03 | Listing compliance update | Positive | +0.3% | NYSE American confirmed resolution of stockholders' equity deficiencies |
| Jul 14 | Public offering | Negative | +10.8% | Upsized equity offering included milestone warrants and potential future proceeds |
| Jun 04 | Structural comparability data | Positive | +0.8% | Presentation of structural and functional ABP-450 comparability data |
| May 14 | 1Q26 earnings report | Positive | -9.9% | FDA pathway feedback, financing, debt reduction, and quarterly cash position |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AEON's historical record showed mixed alignment, with structural and compliance updates aligning positively while earnings and offering-related events diverged.
Key Terms
peptide-mapping technical
disulfide connectivity medical
351(k) biosimilar pathway regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately
- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation
- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX®
- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development
ALISO VIEJO, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced final, expanded primary structure results and preliminary disulfide bond characterization data that provide complementary evidence supporting the molecular similarity of ABP-450 to BOTOX®. The expanded primary structure analysis achieved
“Primary structure is the molecular blueprint of a protein, and disulfide connectivity helps confirm that critical regions of the molecule are covalently linked in the same manner,” said Rob Bancroft, President and Chief Executive Officer of AEON. “Achieving
The expanded primary structure analysis was performed across six drug product samples encompassing both ABP-450 and BOTOX®. Across every region analyzed, the amino acid sequence was identical, including the critical proteolytic activation junction between the light and heavy chains. Because primary sequence is an identity attribute that is not expected to vary between lots, the
The
Preliminary analysis identified the same single disulfide bond (C430-C454) connecting the light and heavy chains in both ABP-450 and BOTOX® across all tested lots, with this disulfide-linked form representing approximately
In March 2026, AEON reported the results of its BPD Type 2a meeting with the U.S. Food and Drug Administration (“FDA” or the “Agency”), which took place in January 2026. During the meeting, the Agency reviewed the Company's proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting the Company's planned analytical development approach. The Agency acknowledged the scientific challenges associated with characterizing a 900 kDa botulinum neurotoxin complex, provided constructive feedback on the Company's proposed development approach and analytical assessment plan, and noted that AEON's analytical methodologies appeared reasonable to support advancement toward a comprehensive analytical similarity package. The Company looks forward to feedback from its planned BPD Type 2b interaction with the FDA in the second half of 2026, which is expected to help inform the next phase of development for ABP-450, including clinical pharmacology and comparative clinical study requirements.
About the U.S. Biosimilar Pathway
The 351(k) biosimilar pathway is grounded in a totality-of-the-evidence approach, with comparative analytical assessment providing the scientific foundation for establishing biosimilarity. The nature and extent of additional studies are informed by the totality of the evidence and any residual uncertainty remaining following comparative analytical assessment. Once biosimilarity is established, FDA may approve a biosimilar for additional indications of the reference product through scientifically justified extrapolation, without requiring separate clinical studies in each indication.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or AEON's future financial or operating performance. For example, statements regarding the qualification of analytical methods, the completion, timing or results of additional analytical testing, the interpretation of the primary structure and preliminary disulfide bond data described in this press release, meetings or discussions with the FDA, the clinical development plan for ABP-450, the potential determination that ABP-450 is highly similar to the reference product, and the potential for full-label U.S. market access are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "plan," "possible," "forecast," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," "potential," or "continue," or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors, many of which are outside of AEON’s control, that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the FDA's response to AEON's primary structure and preliminary disulfide bond results; (ii) AEON's ability to qualify its disulfide bond method and to reproduce or confirm the preliminary results described in this press release, which remain subject to change upon completion of the full analysis; (iii) the timing and results of additional analytical, functional, stability, nonclinical, or clinical testing; (iv) the timing and outcomes of the Company's BPD Type 2b meeting and other meetings or discussions with regulatory authorities; (v) AEON's ability to demonstrate biosimilarity to BOTOX® and to obtain regulatory approval of ABP-450 for the therapeutic indications for which the reference product is approved and for any additional indications, on an accelerated timeline or at all; (vi) AEON’s dependence on Daewoong Pharmaceutical as the sole manufacturer and supplier of ABP-450 and on the continuation of the parties’ license and supply arrangements; (vii) AEON’s ability to obtain, maintain and protect intellectual property rights and the outcome of any legal proceedings that may be instituted against AEON or others; (viii) AEON's future capital requirements, its ability to raise additional financing and its ability to continue as a going concern; (ix) AEON's ability to continue to meet applicable stock exchange listing standards; (x) the possibility that AEON may be adversely affected by economic, business, regulatory, competitive, or other factors; and (xi) other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's filings with the Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov.
Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements, except as required by law.
Contacts Investor
Contact:
Hershel Berry
Blueprint Life Science Group
Hberry@bplifescience.com
Source: AEON Biopharma
